Scott Gottlieb

Scott Gottlieb is Independent Chairman at Illumina, Inc. starting 2025, Independent Director at Pfizer Inc. since 2019, Director at Wesleyan University, The Mount Sinai Health System, Inc., The Mount Sinai Medical Center, Inc., National Resilience, Inc., National Academy of Medicine (United States), Comanche Biopharma Corp.
since 2023, Xaira Therapeutics, Inc. since 2024, and UnitedHealth Group, Inc. starting 2025.
Dr. Gottlieb is Independent Director at Tempus AI, Inc. since 2019, Director at Aetion, Inc. since 2019, Special Partner at NEA Management Co. LLC since 2019, and Partner at New Enterprise Associates, Inc. since 2019.
Former roles include Independent Director at CombiMatrix Corp.
(2009–2016), Managing Director at T.R.
Winston & Co. LLC (2013–2017), Independent Member of the Board of Directors at Bravo Health, Inc. (2009–2011), Member of the Board of Directors at MedAvante, Inc. (2007–2017), Independent Member of the Board of Directors at Molecular Insight Pharmaceuticals, Inc. (2007–2010), Director at Aseko, Inc. and Targeted Medical Pharma, Inc., Director at EMI Holding, Inc. (2015), Independent Member of the Board of Directors at American Pathology Partners, Inc. (2012–2017), Member of the Board of Directors at Gradalis, Inc. (2015–2017), Director at Tolero Pharmaceuticals, Inc. (2015–2016), Independent Member of the Board of Directors at Daiichi Sankyo, Inc. (2015–2017), Member of the Board of Directors at Aptiv Solutions, Inc. (2012–2014), Analyst at Alex.
Brown & Sons, Inc. (1994–1995), Senior Adviser to the Administrator at Centers for Medicare & Medicaid Services (US), Deputy Commissioner-Medical & Scientific Affairs at US Food & Drug Administration (2005–2007), and Commissioner at US Food & Drug Administration (2017–2019).
Education includes undergraduate degree from Wesleyan University and doctorate from Icahn School of Medicine at Mount Sinai.